Last reviewed · How we verify
Etonogestrel/ethinyl estradiol vaginal ring
Etonogestrel and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus, providing contraceptive protection through a vaginal ring delivery system.
Etonogestrel and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus, providing contraceptive protection through a vaginal ring delivery system. Used for Contraception in women of reproductive age.
At a glance
| Generic name | Etonogestrel/ethinyl estradiol vaginal ring |
|---|---|
| Also known as | NuvaRing |
| Sponsor | Andrea Roe, MD, MPH |
| Drug class | Combined hormonal contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Etonogestrel is a progestin that suppresses the luteinizing hormone (LH) surge needed for ovulation, while ethinyl estradiol is an estrogen that provides cycle control and stabilizes the endometrium. Together, they create a hormonal contraceptive effect delivered directly through the vaginal mucosa, allowing for consistent systemic absorption over a 3-week cycle with a 1-week hormone-free interval.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Headache
- Nausea
- Vaginal irritation or discomfort
- Breast tenderness
- Mood changes
- Breakthrough bleeding
Key clinical trials
- Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS (PHASE4)
- Assessing the Impact of Contraceptives on Bone Health Using 41Ca (PHASE4)
- Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (PHASE1)
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012) (PHASE2)
- Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733) (PHASE4)
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062) (PHASE3)
- Inpatient Adolescent Contraception (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: